{
    "root": "4d5cd364-0850-4027-9cba-f3188468d910",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Juluca",
    "value": "20240418",
    "ingredients": [
        {
            "name": "DOLUTEGRAVIR SODIUM",
            "code": "1Q1V9V5WYQ"
        },
        {
            "name": "RILPIVIRINE HYDROCHLORIDE",
            "code": "212WAX8KDD"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "MANNITOL",
            "code": "3OWL53L36A"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "POLYSORBATE 20",
            "code": "7T1F30V5YH"
        },
        {
            "name": "POVIDONE K30",
            "code": "U725QWY32X"
        },
        {
            "name": "SODIUM STARCH GLYCOLATE TYPE A CORN",
            "code": "AG9B65PV6B"
        },
        {
            "name": "SODIUM STEARYL FUMARATE",
            "code": "7CV7WJK4UI"
        }
    ],
    "indications": "juluca indicated complete regimen treatment human immunodeficiency virus type 1 ( hiv-1 ) infection adults replace current antiretroviral regimen virologically suppressed ( hiv-1 rna less 50 copies/ml ) stable antiretroviral regimen least 6 months history treatment failure known substitutions associated resistance individual components juluca .",
    "contraindications": "• one tablet taken orally daily meal . ( 2.1 ) • rifabutin coadministration : take additional 25-mg tablet rilpivirine juluca daily meal duration rifabutin coadministration . ( 2.2 )",
    "warningsAndPrecautions": "juluca tablet contains 50 mg dolutegravir 25 mg rilpivirine , pink , oval , film-coated , biconvex tablet debossed “ sv j3t ” one side . bottle 30 tablets child-resistant closure ( contains desiccant ) ndc 49702-242-13. store dispense original package , protect moisture , keep bottle tightly closed . remove desiccant . store 20°c 25°c ( 68°f 77°f ) ; excursions permitted 15°c 30°c ( 59°f 86°f ) [ usp controlled room temperature ] .",
    "adverseReactions": "juluca contraindicated patients : •with previous hypersensitivity reaction dolutegravir rilpivirine [ ( 5.1 ) ] . •receiving dofetilide due potential increased dofetilide plasma concentrations risk serious and/or life-threatening events [ ( 7 ) ] . •receiving coadministered drugs table 1 significantly decrease rilpivirine plasma concentrations [ ( 7 ) , pharmacology ( 12.3 ) ] . table 1. drugs contraindicated juluca class contraindicated drugs class comment antiarrhythmic dofetilide potential serious and/or life-threatening events due potential increased dofetilide plasma concentrations . anticonvulsants carbamazepine oxcarbazepine phenobarbital phenytoin potential significant decreases rilpivirine plasma concentrations due cytochrome p450 ( cyp ) 3a enzyme induction , may result loss virologic response . antimycobacterials rifampin rifapentine glucocorticoid ( systemic ) dexamethasone ( single-dose treatment ) herbal products st john ’ wort ( hypericum perforatum ) proton pump inhibitors e.g . , esomeprazole lansoprazole omeprazole pantoprazole rabeprazole potential significant decreases rilpivirine plasma concentrations due gastric ph increase , may result loss virologic response .",
    "indications_original": "JULUCA is indicated as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies/mL) on a stable antiretroviral regimen for at least 6 months with no history of treatment failure and no known substitutions associated with resistance to the individual components of JULUCA.",
    "contraindications_original": "• One tablet taken orally once daily with a meal. ( 2.1 ) • Rifabutin coadministration: Take an additional 25-mg tablet of rilpivirine with JULUCA once daily with a meal for the duration of the rifabutin coadministration. ( 2.2 )",
    "warningsAndPrecautions_original": "Each JULUCA tablet contains 50 mg of dolutegravir and 25 mg of rilpivirine, and is a pink, oval, film-coated, biconvex tablet debossed with “SV J3T” on one side.\n                  Bottle of 30 tablets with child-resistant closure (contains a desiccant)       NDC 49702-242-13.\n                  Store and dispense in the original package, protect from moisture, and keep the bottle tightly closed. Do not remove desiccant.\n                  Store at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C and 30°C (59°F and 86°F) [See USP Controlled Room Temperature].",
    "adverseReactions_original": "JULUCA is contraindicated in patients:\n                  \n                     \n                        •with previous hypersensitivity reaction to dolutegravir or rilpivirine [see Warnings and Precautions (5.1)].\n                     \n                        •receiving dofetilide due to the potential for increased dofetilide plasma concentrations and the risk for serious and/or life-threatening events [see Drug Interactions (7)].\n                     \n                        •receiving other coadministered drugs in Table 1 that significantly decrease rilpivirine plasma concentrations [see Drug Interactions (7), Clinical Pharmacology (12.3)].\n                  \n                  \n                     Table 1. Drugs That Are Contraindicated with JULUCA\n                     \n                     \n                     \n                     \n                        \n                           \n                              \n                                 Drug Class\n                              \n                           \n                           \n                              \n                                 Contraindicated Drugs in Class\n                              \n                           \n                           \n                              \n                                 Clinical Comment\n                              \n                           \n                        \n                        \n                           \n                              Antiarrhythmic\n                           \n                           \n                              Dofetilide\n                           \n                           \n                              Potential for serious and/or life-threatening events due to the potential for increased dofetilide plasma concentrations.\n                           \n                        \n                        \n                           \n                              Anticonvulsants\n                           \n                           \n                              Carbamazepine \n                              Oxcarbazepine \n                              Phenobarbital \n                              Phenytoin\n                           \n                           \n                              Potential for significant decreases in rilpivirine plasma concentrations due to cytochrome P450 (CYP)3A enzyme induction, which may result in loss of virologic response.\n                           \n                        \n                        \n                           \n                              Antimycobacterials\n                           \n                           \n                              Rifampin\n                              Rifapentine\n                           \n                        \n                        \n                           \n                              Glucocorticoid (systemic)\n                           \n                           \n                              Dexamethasone\n                              (more than a single-dose treatment)\n                           \n                        \n                        \n                           \n                              Herbal Products\n                           \n                           \n                              St John’s wort \n                              (Hypericum perforatum)\n                           \n                        \n                        \n                           \n                              Proton Pump Inhibitors\n                           \n                           \n                              e.g., Esomeprazole \n                              Lansoprazole \n                              Omeprazole \n                              Pantoprazole \n                              Rabeprazole\n                           \n                           \n                              Potential for significant decreases in rilpivirine plasma concentrations due to gastric pH increase, which may result in loss of virologic response."
}